Menu Back toV5-S3

14th DIA Japan Annual Meeting 2017

[V5-S3] Approaches to Enhance Appropriate Communication on Pharmaceutical Product Information

    Session Chair(s)
      Mamoru  Narukawa, PhD, RPh

      Mamoru Narukawa, PhD, RPh

      • Professor, Department of Clinical Medicine (Pharmaceutical Medicine)
      • Kitasato University, Graduate School of Pharmaceutical Sciences, Japan
      Yuko  Kojima, RPh

      Yuko Kojima, RPh

      • Director, Biometrics, Medicine Development Unit - Japan
      • Eli Lilly Japan K.K., Japan
    It is highly important that pharmaceutical product information is appropriately provided by regulatory authorities and pharmaceutical companies, and utilized in the medical field. In the Japan annual meeting in 2016, we discussed issues arising from provision of pharmaceutical product information materials provided to healthcare professionals or patients, and handling of these issues. We have found that pharmaceutical product information is not necessarily fully utilized by the medical professionals: duplicate information is provided using various materials from the regulatory authorities and companies, necessary information for medical professionals is not provided, and the real intentions of the authors are not fully conveyed. In 2017, we will discuss approaches and future perspectives to enhance appropriate communication on pharmaceutical product information to medical professionals based on the previous discussion by summarizing the objectives and utilization methods of a wide range of information materials provided by the regulatory authorities and companies.
      Tomoko  Tanita

      Tomoko Tanita

      • Risk Communication Promotion Division, Office of Safety I
      • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
      Susumu  Wakabayashi

      Susumu Wakabayashi

      • Department of Pharmacy
      • Kyorin University Hospital, Japan
      Shinya  Takemoto, MSc

      Shinya Takemoto, MSc

      • Group Leader, Drug Safety Coordination Dept., Drug Safety Div.
      • Chugai Pharmaceutical Co., Ltd., Japan
      Junichi  Nishino, MSc, RPh

      Junichi Nishino, MSc, RPh

      • Head, RA Functions Department, Regulatory Office Japan
      • Novartis Pharma K.K., Japan
      Toyotaka  Iguchi, MD, PhD

      Toyotaka Iguchi, MD, PhD

      • Risk Management Director, Office of Safety II
      • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Contact us

Please contact the DIA Japan office in Tokyo for further information.

Tel: +81-3-6214-0574
Fax: +81-3-3278-1313